-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] For advanced solid tumors, domestic patients still have large unmet treatment needs, coupled with considerable market prospects, many pharmaceutical companies have deployed in this field
.
Not long ago, BeiGene's anti-PD-1 monoclonal antibody tislelizumab was approved for a new indication for the treatment of unresectable or metastatic microsatellite highly unstable or mismatch repair gene defects in adults with advanced solid tumors patients, bringing new treatment options to the majority of patients
.
Recently, a large number of drugs for the treatment of advanced solid tumors have been approved for clinical use, involving Hengrui, Henlius, Sunshine Guojian, Livzon Group and other companies
.
SHR-A1811 for injection Hengrui Medicine recently issued an announcement that the company's subsidiary Suzhou Shengdia Biopharmaceutical Co.
, Ltd.
has received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Letter" for SHR-A1811 for injection.
Conduct clinical trials
.
It is reported that SHR-A1811 for injection can bind to HER2-expressing tumor cells and endocytose, release toxins through proteolytic cleavage in tumor cell lysosomes, induce cell cycle arrest and thus induce tumor cell apoptosis.
Use for the treatment of advanced solid tumors with HER2 expression
.
SSGJ-617 Injection Sunshine Guojian announced that recently, the company's SSGJ-617 injection has received the "Drug Clinical Trial Approval Letter" approved and issued by the State Food and Drug Administration for clinical trials of advanced solid tumors, and will launch Phase I in the near future.
clinical trials
.
It is understood that SSGJ-617 is the first antagonistic antibody targeting PSGL-1 in China, which can induce the functional reprogramming of M2-like macrophages and convert them into M1-like phenotypes, thereby producing an anti-tumor pro-inflammatory immune response
.
Compared with current PD-1 therapy, the SSGJ-617 antibody showed a greater pro-inflammatory response and stimulated the immune response
.
It is reported that SSGJ-617 was developed by Verseau Therapeutics, and Sunshine Guojian obtained its rights and interests in Greater China
.
HLX301 Fosun Pharma announced that recently, the application for clinical trials of HLX301 (recombinant human anti-PD-L1 and anti-TIGIT bispecific antibody injection) of Henlius, a holding subsidiary of the company, for the treatment of advanced tumors has been approved by the State Food and Drug Administration.
Bureau approved
.
Henlius plans to conduct Phase I clinical trials of the new drug for the treatment of advanced tumors in China (excluding Hong Kong, Macau and Taiwan, the same below) when conditions are met
.
The new drug is an innovative anti-PD-L1 and anti-TIGIT bispecific antibody independently developed by the Group.
As of the announcement date, no bispecific antibody targeting PD-L1 and anti-TIGIT has been launched globally
.
JS107 for injection Junshi Biotech announced that recently, the company's JS107 for injection was approved by the State Food and Drug Administration to conduct clinical trials for the treatment of advanced malignant solid tumors
.
JS107 is a recombinant humanized anti-Claudin18.
2 monoclonal antibody MMAE (Monomethyl auristatin E) coupling agent for injection independently developed by the company.
It is an antibody-drug conjugate (ADCs) targeting the tumor-related protein Claudin18.
2.
For the treatment of advanced malignant tumors such as gastric cancer and pancreatic cancer
.
LZ001 Tablets Livzon Group announced that on February 22, the company received the "Notice of Approval for Clinical Trials of Drugs" issued by the State Food and Drug Administration, agreeing that the company's LZ001 tablets would carry out clinical trials for advanced solid tumors
.
It is reported that LZ001 tablets are a new generation of anti-drug ROS1/NTRK/ALK multi-target inhibitors jointly developed by Livzon Group and Zhejiang Tongyuankang Pharmaceuticals.
Solid tumors with ALK multi-target mutations
.
According to the Food and Drug Administration and related databases, as of the disclosure date of this announcement, LZ001's similar drug-resistant multi-target chemicals have not yet been launched in China
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Not long ago, BeiGene's anti-PD-1 monoclonal antibody tislelizumab was approved for a new indication for the treatment of unresectable or metastatic microsatellite highly unstable or mismatch repair gene defects in adults with advanced solid tumors patients, bringing new treatment options to the majority of patients
.
Recently, a large number of drugs for the treatment of advanced solid tumors have been approved for clinical use, involving Hengrui, Henlius, Sunshine Guojian, Livzon Group and other companies
.
SHR-A1811 for injection Hengrui Medicine recently issued an announcement that the company's subsidiary Suzhou Shengdia Biopharmaceutical Co.
, Ltd.
has received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Letter" for SHR-A1811 for injection.
Conduct clinical trials
.
It is reported that SHR-A1811 for injection can bind to HER2-expressing tumor cells and endocytose, release toxins through proteolytic cleavage in tumor cell lysosomes, induce cell cycle arrest and thus induce tumor cell apoptosis.
Use for the treatment of advanced solid tumors with HER2 expression
.
SSGJ-617 Injection Sunshine Guojian announced that recently, the company's SSGJ-617 injection has received the "Drug Clinical Trial Approval Letter" approved and issued by the State Food and Drug Administration for clinical trials of advanced solid tumors, and will launch Phase I in the near future.
clinical trials
.
It is understood that SSGJ-617 is the first antagonistic antibody targeting PSGL-1 in China, which can induce the functional reprogramming of M2-like macrophages and convert them into M1-like phenotypes, thereby producing an anti-tumor pro-inflammatory immune response
.
Compared with current PD-1 therapy, the SSGJ-617 antibody showed a greater pro-inflammatory response and stimulated the immune response
.
It is reported that SSGJ-617 was developed by Verseau Therapeutics, and Sunshine Guojian obtained its rights and interests in Greater China
.
HLX301 Fosun Pharma announced that recently, the application for clinical trials of HLX301 (recombinant human anti-PD-L1 and anti-TIGIT bispecific antibody injection) of Henlius, a holding subsidiary of the company, for the treatment of advanced tumors has been approved by the State Food and Drug Administration.
Bureau approved
.
Henlius plans to conduct Phase I clinical trials of the new drug for the treatment of advanced tumors in China (excluding Hong Kong, Macau and Taiwan, the same below) when conditions are met
.
The new drug is an innovative anti-PD-L1 and anti-TIGIT bispecific antibody independently developed by the Group.
As of the announcement date, no bispecific antibody targeting PD-L1 and anti-TIGIT has been launched globally
.
JS107 for injection Junshi Biotech announced that recently, the company's JS107 for injection was approved by the State Food and Drug Administration to conduct clinical trials for the treatment of advanced malignant solid tumors
.
JS107 is a recombinant humanized anti-Claudin18.
2 monoclonal antibody MMAE (Monomethyl auristatin E) coupling agent for injection independently developed by the company.
It is an antibody-drug conjugate (ADCs) targeting the tumor-related protein Claudin18.
2.
For the treatment of advanced malignant tumors such as gastric cancer and pancreatic cancer
.
LZ001 Tablets Livzon Group announced that on February 22, the company received the "Notice of Approval for Clinical Trials of Drugs" issued by the State Food and Drug Administration, agreeing that the company's LZ001 tablets would carry out clinical trials for advanced solid tumors
.
It is reported that LZ001 tablets are a new generation of anti-drug ROS1/NTRK/ALK multi-target inhibitors jointly developed by Livzon Group and Zhejiang Tongyuankang Pharmaceuticals.
Solid tumors with ALK multi-target mutations
.
According to the Food and Drug Administration and related databases, as of the disclosure date of this announcement, LZ001's similar drug-resistant multi-target chemicals have not yet been launched in China
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
